OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 05:50 UTC. Every row links to its source record.

RREB1 ras responsive element binding protein 1

ENSG00000124782 · protein coding · Open Targets profile

Transcription factor that binds specifically to the RAS- responsive elements (RRE) of gene promoters (PubMed:10390538, PubMed:15067362, PubMed:17550981, PubMed:8816445, PubMed:9305772). Represses the angiotensinogen gene (PubMed:15067362). Negatively regulates the transcriptional activity of AR (PubMed:17550981). Potentiates the transcriptional activity of NEUROD1 (PubMed:12482979). Promotes brown adipocyte differentiation (By similarity). May be involved in Ras/Raf-mediated cell differentiation by enhancing calcitonin expression (PubMed:8816445). {ECO:0000250|UniProtKB:Q3UH06, ECO:0000269|PubMed:10390538, ECO:0000269|PubMed:12482979, ECO:0000269|PubMed:15067362, ECO:0000269|PubMed:17550981, ECO:0000269|PubMed:8816445, ECO:0000269|PubMed:9305772}.

In 7 of 10 cancers, the evidence for RREB1 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751colorectal cancercolorectal cancercolorectal cancer: germline 0.46breast carcinomabreast carcinomabreast carcinoma: germline 0.56Ewing sarcomaEwing sarcomaEwing sarcoma: germline 0.51B-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemia: germline 0.49uveal melanomauveal melanomauveal melanoma: germline 0.39cutaneous melanomacutaneous melanomacutaneous melanoma: germline 0.43connective tissue neoplasmconnective tissue neoplasmconnective tissue neoplasm: germline 0.36melanomamelanomacolorectal carcinomacolorectal carcinomaacute myeloid leukemiaacute myeloid leukemia

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.22924000024795532 (upper bound 0.31613999605178833). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of RREB1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of RREB1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.